326 related articles for article (PubMed ID: 34263141)
1. Next-generation cytokines for cancer immunotherapy.
Xue D; Hsu E; Fu YX; Peng H
Antib Ther; 2021 Apr; 4(2):123-133. PubMed ID: 34263141
[TBL] [Abstract][Full Text] [Related]
2. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
Xiang J
Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
[TBL] [Abstract][Full Text] [Related]
3. Engineering cytokines for cancer immunotherapy: a systematic review.
Fu Y; Tang R; Zhao X
Front Immunol; 2023; 14():1218082. PubMed ID: 37483629
[TBL] [Abstract][Full Text] [Related]
4. Cytokines that target immune killer cells against tumors.
Qiao J; Fu YX
Cell Mol Immunol; 2020 Jul; 17(7):722-727. PubMed ID: 32523115
[TBL] [Abstract][Full Text] [Related]
5. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
7. The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
Wang Y; Zhang H; He YW
Front Immunol; 2019; 10():1574. PubMed ID: 31379815
[TBL] [Abstract][Full Text] [Related]
8. Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.
Tomasovic LM; Liu K; VanDyke D; Fabilane CS; Spangler JB
BioDrugs; 2024 Mar; 38(2):227-248. PubMed ID: 37999893
[TBL] [Abstract][Full Text] [Related]
9. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
10. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
Kermer V; Baum V; Hornig N; Kontermann RE; Müller D
Mol Cancer Ther; 2012 Jun; 11(6):1279-88. PubMed ID: 22491823
[TBL] [Abstract][Full Text] [Related]
11. Targeted antibody and cytokine cancer immunotherapies through collagen affinity.
Ishihara J; Ishihara A; Sasaki K; Lee SS; Williford JM; Yasui M; Abe H; Potin L; Hosseinchi P; Fukunaga K; Raczy MM; Gray LT; Mansurov A; Katsumata K; Fukayama M; Kron SJ; Swartz MA; Hubbell JA
Sci Transl Med; 2019 Apr; 11(487):. PubMed ID: 30971453
[TBL] [Abstract][Full Text] [Related]
12. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
13. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
14. Cytokine engineering for targeted cancer immunotherapy.
Bonati L; Tang L
Curr Opin Chem Biol; 2021 Jun; 62():43-52. PubMed ID: 33684633
[TBL] [Abstract][Full Text] [Related]
15. Characteristic cytokine generation patterns in cancer cells and infiltrating lymphocytes in oral squamous cell carcinomas and the influence of chemoradiation combined with immunotherapy on these patterns.
Yamamoto T; Kimura T; Ueta E; Tatemoto Y; Osaki T
Oncology; 2003; 64(4):407-15. PubMed ID: 12759539
[TBL] [Abstract][Full Text] [Related]
16. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
Young PA; Morrison SL; Timmerman JM
Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
[TBL] [Abstract][Full Text] [Related]
17. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
18. Advances in engineering and delivery strategies for cytokine immunotherapy.
Bohmer M; Xue Y; Jankovic K; Dong Y
Expert Opin Drug Deliv; 2023 May; 20(5):579-595. PubMed ID: 37104673
[TBL] [Abstract][Full Text] [Related]
19. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity.
Hu P; Mizokami M; Ruoff G; Khawli LA; Epstein AL
Blood; 2003 Jun; 101(12):4853-61. PubMed ID: 12609842
[TBL] [Abstract][Full Text] [Related]
20. The application of Interleukin-2 family cytokines in tumor immunotherapy research.
Zhou Y; Quan G; Liu Y; Shi N; Wu Y; Zhang R; Gao X; Luo L
Front Immunol; 2023; 14():1090311. PubMed ID: 36936961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
